Destination known: Targeted drug delivery in atherosclerosis and thrombosis

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Preclinical Research Atherosclerosis and its sequelae are key contributors to overall human morbidity and mortality worldwide. Substantial effort has been made toward the understanding of disease mechanisms and particularly treatment options. Drugs for primary and secondary prevention of atherosclerosis and in particular its complications, e.g., myocardial infarction, are widely used therapeutics. However, those drugs typically act nonspecifically, thus affecting not only target cells and atherosclerotic lesions but also causing unwanted side effects. One of the most promising recent developments are drugs that exclusively act at the site where they are needed and thereby minimize deleterious side effects. This review focuses on new approaches for targeted drug delivery, emphasizing single-chain antibody constructs, liposomal formulations, and microRNAs/gene delivery to sites of atherosclerosis and thrombosis.

Original languageEnglish
Pages (from-to)460-471
Number of pages12
JournalDrug Development Research
Volume74
Issue number7
DOIs
Publication statusPublished - 2013
Externally publishedYes

Keywords

  • atherosclerosis
  • targeted drug delivery
  • thrombosis

Cite this

@article{c62582a35e7a4b89a739acfd499c8f72,
title = "Destination known: Targeted drug delivery in atherosclerosis and thrombosis",
abstract = "Preclinical Research Atherosclerosis and its sequelae are key contributors to overall human morbidity and mortality worldwide. Substantial effort has been made toward the understanding of disease mechanisms and particularly treatment options. Drugs for primary and secondary prevention of atherosclerosis and in particular its complications, e.g., myocardial infarction, are widely used therapeutics. However, those drugs typically act nonspecifically, thus affecting not only target cells and atherosclerotic lesions but also causing unwanted side effects. One of the most promising recent developments are drugs that exclusively act at the site where they are needed and thereby minimize deleterious side effects. This review focuses on new approaches for targeted drug delivery, emphasizing single-chain antibody constructs, liposomal formulations, and microRNAs/gene delivery to sites of atherosclerosis and thrombosis.",
keywords = "atherosclerosis, targeted drug delivery, thrombosis",
author = "Erik Westein and Ulrike Flierl and Hagemeyer, {Christoph E.} and Karlheinz Peter",
year = "2013",
doi = "10.1002/ddr.21103",
language = "English",
volume = "74",
pages = "460--471",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "Wiley-Blackwell",
number = "7",

}

Destination known : Targeted drug delivery in atherosclerosis and thrombosis. / Westein, Erik; Flierl, Ulrike; Hagemeyer, Christoph E.; Peter, Karlheinz.

In: Drug Development Research, Vol. 74, No. 7, 2013, p. 460-471.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Destination known

T2 - Targeted drug delivery in atherosclerosis and thrombosis

AU - Westein, Erik

AU - Flierl, Ulrike

AU - Hagemeyer, Christoph E.

AU - Peter, Karlheinz

PY - 2013

Y1 - 2013

N2 - Preclinical Research Atherosclerosis and its sequelae are key contributors to overall human morbidity and mortality worldwide. Substantial effort has been made toward the understanding of disease mechanisms and particularly treatment options. Drugs for primary and secondary prevention of atherosclerosis and in particular its complications, e.g., myocardial infarction, are widely used therapeutics. However, those drugs typically act nonspecifically, thus affecting not only target cells and atherosclerotic lesions but also causing unwanted side effects. One of the most promising recent developments are drugs that exclusively act at the site where they are needed and thereby minimize deleterious side effects. This review focuses on new approaches for targeted drug delivery, emphasizing single-chain antibody constructs, liposomal formulations, and microRNAs/gene delivery to sites of atherosclerosis and thrombosis.

AB - Preclinical Research Atherosclerosis and its sequelae are key contributors to overall human morbidity and mortality worldwide. Substantial effort has been made toward the understanding of disease mechanisms and particularly treatment options. Drugs for primary and secondary prevention of atherosclerosis and in particular its complications, e.g., myocardial infarction, are widely used therapeutics. However, those drugs typically act nonspecifically, thus affecting not only target cells and atherosclerotic lesions but also causing unwanted side effects. One of the most promising recent developments are drugs that exclusively act at the site where they are needed and thereby minimize deleterious side effects. This review focuses on new approaches for targeted drug delivery, emphasizing single-chain antibody constructs, liposomal formulations, and microRNAs/gene delivery to sites of atherosclerosis and thrombosis.

KW - atherosclerosis

KW - targeted drug delivery

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84886442909&partnerID=8YFLogxK

U2 - 10.1002/ddr.21103

DO - 10.1002/ddr.21103

M3 - Review Article

VL - 74

SP - 460

EP - 471

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 7

ER -